论文部分内容阅读
目的探寻渗透泵强化对流释放给药治疗脑肿瘤的祼小鼠模型,为新药的临床前期应用提供良好的实验动物模型。方法 14只祼小鼠基底节区种植4×105个人胶质瘤U87细胞,并安置渗透泵强化对流释放给药系统。裸小鼠按体重和活体荧光信号强度分为二组:治疗组(n=7)的泵内注入100μl(1μg)的DTATEGF,对照组(n=7)泵内注入100μl(1μg)的无关毒素DT。观察动物的生长特征,Kaplan-Meier生存曲线分析和脑内肿瘤的病理学特征。结果实验动物没有与渗透泵及外科手术相关的病残和病死发生。动物对渗透泵给药系统耐受好,无抓搔及渗透泵脱位,伤口无感染及裂开等情况。Kaplan-Meier生存曲线显示治疗组动物的中位生存期较对照组明显延长,差异有显著性。(治疗组126天vs.对照组68天,P=0.0002)。治疗组中有两只小鼠生存期超过180天。病理学检测祼小鼠脑内种植生长的肿瘤与人类胶质母细胞瘤的病理特征极为相似。结论该祼小鼠实验动物模型简便、实用、可靠,适用于新的药物包括单克隆抗体、靶向小分子、肿瘤疫苗等通过强化对流投递治疗脑内恶性肿瘤的临床前期应用。
Objective To investigate the osmotic pump to strengthen the convection-release drug treatment of brain tumors of the mouse model of 祼, for the clinical application of new drugs to provide a good experimental animal model. Methods Twenty - four mouse U87 cells were seeded in the basal ganglia of mice. The osmotic pump was used to strengthen the convection - release drug delivery system. Nude mice were divided into two groups according to the body weight and the fluorescence signal intensity of living body: 100 μl (1 μg) of DTATEGF was injected into the pump of the treatment group (n = 7), and 100 μl (1 μg) of irrelevant toxin DT. The growth characteristics of animals were observed, Kaplan-Meier survival curve analysis and pathological features of brain tumors. Results There was no morbidity and mortality in experimental animals associated with osmotic pumps and surgery. Animal osmotic pump delivery system is well tolerated, no scratching and osmotic pump dislocation, no wound infection and split and so on. Kaplan-Meier survival curves showed that the median survival time of treatment group was significantly longer than that of control group, the difference was significant. (126 days in the treatment group vs 68 days in the control group, P = 0.0002). Two mice in the treatment group survived for more than 180 days. Pathological tests 肿 The growth of tumors in the brain of mice is very similar to that of human glioblastoma. Conclusion The model of experimental mice is simple, practical and reliable. It is suitable for the preclinical application of new drugs including monoclonal antibodies, target small molecules and tumor vaccines in the treatment of intracranial malignant tumors by intensive convection delivery.